Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Brief summary

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

acronym

SELECT

status

COMPLETED

phase

PHASE3

study type

INTERVENTIONAL

enrollment

17604

sponsor

Novo Nordisk A/S

conditions

Overweight; Obesity

interventions

DRUG: Semaglutide; DRUG: Placebo (semaglutide)

start date

2018-10-24

start date type

ACTUAL

primary completion date

2023-06-21

has results

true

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters